SCHEDULE 13G/A: Vivo Opportunity Fund Discloses 3.9% Passive Stake in Regulus Therapeutics
Beneficial Ownership Report Amendment
Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have filed an amended Schedule 13G, disclosing a 3.9% passive beneficial ownership in Regulus Therapeutics Inc.
Summary
- Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC collectively hold 2,696,426 shares of Regulus Therapeutics Inc. common stock.
- This beneficial ownership represents 3.9% of Regulus Therapeutics Inc.'s outstanding common stock.
- The percentage is calculated based on 69,234,089 shares of common stock outstanding as of May 2, 2025, as reported in Regulus Therapeutics Inc.'s Quarterly Report on Form 10-Q filed on May 8, 2025.
- Both Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC are Delaware entities.
- The reporting persons have sole voting and sole dispositive power over all 2,696,426 shares.
- The filing confirms that the securities were not acquired or held for the purpose of changing or influencing the control of Regulus Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing a passive ownership stake. It contains factual information about shareholdings and does not inherently convey positive or negative sentiment regarding the company's operational or financial performance.
Positives
- The continued holding of a significant, albeit passive, stake by an institutional investor like Vivo Opportunity Fund may signal ongoing confidence in Regulus Therapeutics Inc.'s long-term prospects.
- The passive nature of the investment, as indicated by the Schedule 13G filing, suggests no immediate intent by Vivo Opportunity Fund to seek control or influence management, providing stability for current corporate governance.
Negatives
- The 3.9% stake is below the 5% threshold that typically triggers more detailed Schedule 13D filings, indicating that Vivo Opportunity Fund is not an activist investor in Regulus Therapeutics Inc.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Regulus Therapeutics Inc. or the reporting persons regarding the company's future performance.
Industry Context
This filing is a routine disclosure of an institutional investor's passive stake in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive dynamics beyond confirming an investor's position.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, passive institutional holder's stake, confirming no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement |
| 05/02/2025 | Date as of which 69,234,089 shares of Common Stock were outstanding, as disclosed in Issuer's Form 10-Q |
| 05/08/2025 | Date Regulus Therapeutics Inc. filed its Quarterly Report on Form 10-Q with the SEC |
| 05/14/2025 | Date of signing and filing of this Schedule 13G Amendment No. 1 |
Keywords
Regulus Therapeutics, Vivo Opportunity Fund, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.